Michel M Attal

List of Publications by Year
in descending order

269 papers	28,931 citations	5896 81 h-index	5255 165 g-index
271 all docs	271 docs citations	271 times ranked	12802 citing authors

#	Article	IF	Citations
1	A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma. New England Journal of Medicine, 1996, 335, 91-97.	27.0	2,550
2	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 2015, 33, 2863-2869.	1.6	1,525
3	Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1782-1791.	27.0	1,022
4	Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2003, 349, 2495-2502.	27.0	938
5	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. New England Journal of Medicine, 2017, 376, 1311-1320.	27.0	924
6	Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myèlome. Blood, 2007, 109, 3489-3495.	1.4	845
7	Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99â€“06): a randomised trial. Lancet, The, 2007, 370, 1209-1218.	13.7	820
8	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications, 2014, 5, 2997.	12.8	741
9	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. New England Journal of Medicine, 2014, 371, 906-917.	27.0	697
10	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 2016, 127, 2955-2962.	1.4	686
11	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. New England Journal of Medicine, 2019, 380, 2104-2115.	27.0	684
12	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 29-38.	13.7	665
13	Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 2006, 108, 3289-3294.	1.4	639
14	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Journal of Clinical Oncology, 2017, 35, 3279-3289.	1.6	535
15	Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood, 2002, 99, 731-735.	1.4	531
16	Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. Journal of Clinical Oncology, 2010, 28, 4621-4629.	1.6	512
17	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p). Journal of Clinical Oncology, 2010, 28, 4630-4634.	1.6	383
18	Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du MyÃ©lome. Journal of Clinical Oncology, 2008, 26, 4798-4805.	1.6	361

#	Article	IF	Citations
19	Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the SociÃ©tÃ© FranÃ§aise de Greffe de Moelle. Journal of Clinical Oncology, 2000, 18, 537-537.	1.6	357
20	Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood, 2006, 107, 3474-3480.	1.4	344
21	Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 2003, 102, 4284-4289.	1.4	306
22	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 2018, 132, 2456-2464.	1.4	301
23	Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the SociÃ©tÃ© FranÃ§aise de Greffe de MoÃ«lle et de ThÃ©rapie Cellulaire. Journal of Clinical Oncology, 2008, 26, 2264-2271.	1.6	284
24	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 2011, 117, 6063-6073.	1.4	282
25	Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood, 2011, 118, 5752-5758.	1.4	275
26	Prognostic Significance of Copy-Number Alterations in Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 4585-4590.	1.6	258
27	Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. Journal of Clinical Oncology, 2017, 35, 2911-2918.	1.6	247
28	Frontline therapy of multiple myeloma. Blood, 2015, 125, 3076-3084.	1.4	244
29	Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du MyÃ©lome. Journal of Clinical Oncology, 2014, 32, 2712-2717.	1.6	243
30	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. Journal of Clinical Oncology, 2013, 31, 3279-3287.	1.6	238
31	Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica, 2006, 91, 1498-505.	3.5	233
32	VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood, 2016, 127, 2569-2574.	1.4	224
33	Antiâ€“B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 775-783.	1.6	222
34	Prognostic factors for survival and response after highâ€dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematology, 1998, 101, 766-769.	2.5	219
35	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood, 2018, 131, 301-310.	1.4	216
36	The role of complete response in multiple myeloma. Blood, 2009, 114, 3139-3146.	1.4	206

#	Article	IF	Citations
37	Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomideâ€“refractory multiple myeloma: Intergroupe Francophone du MyÃ©lome 2009-02. Blood, 2013, 121, 1968-1975.	1.4	201
38	Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival. Journal of Clinical Oncology, 2012, 30, 1949-1952.	1.6	198
39	Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. European Journal of Immunology, 1993, 23, 820-824.	2.9	195
40	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10â€‰549 patients from the International Myeloma Working Group. Blood, 2008, 111, 4039-4047.	1.4	190
41	IMWG consensus on maintenance therapy in multiple myeloma. Blood, 2012, 119, 3003-3015.	1.4	178
42	Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood, 2002, 100, 3128-3134.	1.4	174
43	Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood, 2006, 107, 1292-1298.	1.4	174
44	Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia, 2013, 27, 711-717.	7.2	174
45	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2019, 6, e448-e458.	4.6	168
46	Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood, 2008, 112, 4445-4451.	1.4	164
47	Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet, The, 1999, 354, 1092-1093.	13.7	159
48	Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology, 2006, 135, 158-164.	2.5	155
49	Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials. Journal of Clinical Oncology, 2009, 27, 5720-5726.	1.6	155
50	Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du MyÃ©lome (IFM). Blood, 2010, 115, 32-37.	1.4	152
51	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progressionâ€“Related Death. Journal of Clinical Oncology, 2014, 32, 2173-2180.	1.6	150
52	Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study. Journal of Clinical Oncology, 1999, 17, 222-222.	1.6	147
53	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, BloodÂand Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146
54	Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. Journal of Clinical Oncology, 2010, 28, 1209-1214.	1.6	144

#	Article	IF	Citations
55	Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. Journal of Clinical Oncology, 2010, 28, 1599-1605.	1.6	142
56	Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies. Journal of Clinical Oncology, 2011, 29, 1898-1906.	1.6	126
57	Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica, 2010, 95, 1973-1976.	3.5	124
58	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. Blood, 2011, 117, 2009-2011.	1.4	115
59	Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. Journal of Clinical Oncology, 2019, 37, 1657-1665.	1.6	111
60	Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood, 2008, 112, 3914-3915.	1.4	110
61	Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica, 2010, 95, 1738-1744.	3.5	109
62	Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood, 2011, 117, 3041-3044.	1.4	109
63	Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplantation, 2015, 50, 209-215.	2.4	108
64	Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du MyÃ©lome Experience. Journal of Clinical Oncology, 2013, 31, 2806-2809.	1.6	103
65	High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis BasedÂonÂData from the European Blood and MarrowÂTransplantation Registry. Biology of Blood and Marrow Transplantation, 2012, 18, 788-793.	2.0	102
66	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Annals of Oncology, 2017, 28, 228-245.	1.2	102
67	Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood, 2013, 121, 2618-2626.	1.4	100
68	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood, 2015, 126, 391-391.	1.4	99
69	Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood, 2006, 107, 397-403.	1.4	94
70	Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia, 2018, 32, 2636-2647.	7.2	94
71	Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2014, 49, 389-396.	2.4	92
72	Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?. Blood, 2015, 126, 2713-2719.	1.4	92

#	Article	IF	Citations
73	Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia, 2014, 28, 675-679.	7.2	91
74	Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood, 2015, 125, 1411-1417.	1.4	91
75	Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial. Blood, 1999, 94, 1218-1225.	1.4	90
76	Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma. Cancer Research, 2012, 72, 1395-1406.	0.9	90
77	Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. British Journal of Haematology, 2000, 111, 292-302.	2.5	89
78	In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. European Journal of Immunology, 1991, 21, 1759-1762.	2.9	87
79	Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome. Journal of Clinical Oncology, 2001, 19, 3340-3349.	1.6	87
80	Genomics of Multiple Myeloma. Journal of Clinical Oncology, 2017, 35, 963-967.	1.6	85
81	Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood, 2001, 97, 3669-3671.	1.4	83
82	Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica, 2007, 92, 627-634.	3.5	83
83	Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood, 2015, 125, 2095-2100.	1.4	82
84	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17.	6.2	75
85	Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2008, 26, 3183-3188.	1.6	73
86	Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival. Clinical Cancer Research, 2011, 17, 1253-1263.	7.0	72
87	Thalidomide in patients with advanced multiple myeloma: a study of 83 patientsâ€“report of the intergroupe francophone du myÃ©lome (IFM). The Hematology Journal, 2002, 3, 185-192.	1.4	71
88	Prognostic utility of intact immunoglobulin Igâ€²Îº/Igâ€²Î» ratios in multiple myeloma patients. Leukemia, 2013, 27, 202-207.	7.2	69
89	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	7.1	67
90	Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Future Oncology, 2018, 14, 1035-1047.	2.4	65

#	Article	IF	Citations
91	The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplantation, 2013, 48, 1409-1414.	2.4	63
92	Improved outcome for AML patients over the years 2000â€“2014. Blood Cancer Journal, 2017, 7, 635.	6.2	63
93	Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience. Journal of Clinical Oncology, 2005, 23, 7676-7684.	1.6	59
94	Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the SociÃ©tÃ© FranÃ§aise de Greffe de Moelle et de ThÃ©rapie Cellulaire. Experimental Hematology, 2008, 36, 535-544.	0.4	58
95	Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood, 2016, 128, 2941-2948.	1.4	58
96	How I treat first relapse of myeloma. Blood, 2017, 130, 963-973.	1.4	58
97	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. Blood, 2013, 122, 767-767.	1.4	56
98	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood, 2018, 132, 2555-2563.	1.4	54
99	A predictive model for risk of early gradeâ€‰â‰¥â€‰3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia, 2018, 32, 1404-1413.	7.2	53
100	Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia, 2013, 27, 2242-2244.	7.2	52
101	VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial.. Blood, 2007, 110, 450-450.	1.4	51
102	Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02.. Blood, 2010, 116, 310-310.	1.4	50
103	Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. Blood, 2015, 126, 191-191.	1.4	50
104	A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia. Leukemia and Lymphoma, 1998, 31, 343-349.	1.3	49
105	Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood, 2010, 116, 3157-3162.	1.4	49
106	Higher Incidence of Relapse With Peripheral Blood Rather Than Marrow As a Source of Stem Cells in Adults With Acute Myelocytic Leukemia Autografted During the First Remission. Journal of Clinical Oncology, 2009, 27, 3987-3993.	1.6	48
107	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia, 2018, 32, 2626-2635.	7.2	48
108	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood, 2015, 125, 3100-3104.	1.4	47

#	Article	IF	Citations
109	Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemotherapy and Pharmacology, 1993, 32, 379-384.	2.3	46
110	The Use of a Sequential High Dose Recombinant Interleukin 2 Regimen After Autologous Bone Marrow Transplantation Does Not Improve the Disease Free Survival of Patients with Acute Leukemia Transplanted in First Complete Remission. Leukemia and Lymphoma, 1997, 25, 469-478.	1.3	46
111	Randomized trial experience of the Intergroupe Francophone du MyÃ©lome. Seminars in Hematology, 2001, 38, 226-230.	3.4	44
112	Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica, 2020, 105, e480-483.	3.5	42
113	STANDARD THERAPY VERSUS AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA. Hematology/Oncology Clinics of North America, 1997, 11, 133-146.	2.2	41
114	Lenalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: Follow-Up Analysis Of The IFM 2005-02 Trial. Blood, 2013, 122, 406-406.	1.4	41
115	Large-scale expansion and transplantation of CD34+ hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity. Transfusion, 2006, 46, 1934-1942.	1.6	40
116	Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf (Pts) Ineligible For Stem Cell Transplantation (SCT). Blood, 2013, 122, 2-2.	1.4	39
117	Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica, 2010, 95, 996-1003.	3.5	38
118	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clinical Cancer Research, 2016, 22, 4350-4355.	7.0	38
119	Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer Journal, 2019, 9, 39.	6.2	38
120	The role of stem cell transplantation in multiple myeloma. Blood Reviews, 2002, 16, 245-253.	5.7	37
121	Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyÃ©Lome (IFM) Krd Phase II Study. Blood, 2016, 128, 1142-1142.	1.4	36
122	Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Reviews, 2009, 23, 87-93.	5.7	35
123	Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. Haematologica, 2014, 99, 1236-1238.	3.5	35
124	Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?. Bone Marrow Transplantation, 2015, 50, 1024-1029.	2.4	31
125	Hemolyticâ€Uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. American Journal of Hematology, 1994, 47, 254-255.	4.1	28
126	Role of autologous stem-cell transplantation in multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 747-759.	1.7	25

#	Article	IF	Citations
127	Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica, 2016, 101, 356-362.	3.5	25
128	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. Blood, 2014, 124, 638-638.	1.4	25
129	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of Î”SUVmax in the FDG-Avid Patients of the IMAJEM Study. Clinical Cancer Research, 2018, 24, 5219-5224.	7.0	24
130	Oligonucleotide clonospecific probes directed against the junctional sequence of t(14;18): a new tool for the assessment of minimal residual disease in follicular lymphomas. British Journal of Haematology, 1996, 94, 676-684.	2.5	23
131	Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft. British Journal of Haematology, 2001, 114, 698-700.	2.5	22
132	Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood, 2021, 138, 113-121.	1.4	22
133	Stem-cell transplantation in multiple myeloma. Best Practice and Research in Clinical Haematology, 2005, 18, 603-618.	1.7	21
134	Logic programming reveals alteration of key transcription factors in multiple myeloma. Scientific Reports, 2017, 7, 9257.	3.3	20
135	Firstline Treatment and Maintenance in Newly Diagnosed Multiple Myeloma Patients. Recent Results in Cancer Research, 2011, 183, 189-206.	1.8	20
136	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. Blood, 2018, 132, 257-257.	1.4	20
137	The Prognostic Impact of Complete Remission (CR) Plus Very Good Partial Remission (VGPR) in a Double-Transplantation Program for Newly Diagnosed Multiple Myeloma (MM). Combined Results of the IFM 99 Trials.. Blood, 2006, 108, 3077-3077.	1.4	20
138	High Complete and Very Good Partial Response Rates with Bortezomibâ€"Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial.. Blood, 2009, 114, 353-353.	1.4	20
139	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. Blood, 2015, 126, 395-395.	1.4	20
140	Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. Experimental Hematology, 2013, 41, 1008-1015.	0.4	19
141	Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. Bone Marrow Transplantation, 2014, 49, 671-678.	2.4	18
142	Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). Blood, 2018, 132, 2778-2780.	1.4	18
143	Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Leukemia and Lymphoma, 2020, 61, 1323-1333.	1.3	18
144	The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Expert Review of Hematology, 2014, 7, 55-66.	2.2	17

#	Article	IF	Citations
145	Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia, 2019, 33, 313-318.	7.2	17
146	Association of the Philadelphia chromosome and 5qâ˜ in secondary blood disorder. Cancer Genetics and Cytogenetics, 1988, 30, 253-259.	1.0	16
147	The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents. Seminars in Hematology, 2009, 46, 127-132.	3.4	16
148	Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyÃ©Lome (IFM). Blood, 2016, 128, 674-674.	1.4	16
149	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood, 2022, 139, 2747-2757.	1.4	16
150	A Pilot Study of Autologous Bone Marrow Transplantation Followed by Recombinant Interleukin-2 in Malignant Lymphomas. Leukemia and Lymphoma, 1996, 21, 107-114.	1.3	15
151	DKK1 and sclerostin are early markers of relapse in multiple myeloma. Bone, 2018, 113, 114-117.	2.9	15
152	One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy. Frontiers in Immunology, 2018, 9, 704.	4.8	15
153	Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).. Blood, 2009, 114, 354-354.	1.4	15
154	Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial. Blood, 2015, 126, 730-730.	1.4	15
155	Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Best Practice and Research in Clinical Haematology, 1999, 12, 171-191.	1.7	14
156	Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma: Final Analysis of a Prospective Randomized Study of the â€œIntergroupe Francophone du Myelomeâ€•. Blood, 2005, 106, 1148-1148.	1.4	14
157	Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.. Blood, 2006, 108, 3554-3554.	1.4	14
158	Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study. Blood, 2010, 116, 624-624.	1.4	14
159	Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma ?: a Retrospective Study From the Lymphoma Working Party of the EBMT. Blood, 2010, 116, 688-688.	1.4	14
160	Vitamin D deficiency does not alter biochemical markers of bone metabolism before or after autograft in patients with multiple myeloma. European Journal of Haematology, 2010, 85, 65-7.	2.2	13
161	All transplantation-eligible patients with myeloma should receive ASCT in first response. Hematology American Society of Hematology Education Program, 2014, 2014, 250-254.	2.5	13
162	Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).. Blood, 2006, 108, 3551-3551.	1.4	13

#	Article	IF	Citations
163	Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program. Blood, 2011, 118, 1872-1872.	1.4	13
164	1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients. Blood, 2012, 120, 933-933.	1.4	13
165	One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. British Journal of Haematology, 2005, 129, 403-410.	2.5	12
166	Dualâ€energy Xâ€ray absorptiometry and biochemical markers of bone turnover after autologous stem cell transplantation in myeloma. European Journal of Haematology, 2012, 88, 388-395.	2.2	12
167	The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma. Clinical Cancer Research, 2013, 19, 4634-4637.	7.0	12
168	Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial. Clinical Cancer Research, 2019, 25, 4224-4230.	7.0	12
169	High-dose therapy in multiple myeloma. The Hematology Journal, 2003, 4, 163-170.	1.4	12
170	Epstein-Barr virus in familial Hodgkin's disease. British Journal of Haematology, 1994, 88, 636-638.	2.5	11
171	Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e228-e237.	0.4	11
172	Induction with VelcadeÂ®/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma.. Blood, 2009, 114, 957-957.	1.4	11
173	Final Analysis of Overall Survival from the First Trial. Blood, 2016, 128, 241-241.	1.4	11
174	Early Allogeneic Bone Marrow Transplantation for Young Adults with Acute Myeloid Leukemia in First Complete Remission: The 17 Year Experience of the BGMT Group.. Blood, 2004, 104, 619-619.	1.4	11
175	Patients Under 50 Years of Age Do Not Present Specific Prognostic Characteristics: An IFM Study in 1897 Patients Under 65 Years of Age.. Blood, 2009, 114, 2837-2837.	1.4	11
176	Stem Cell Transplantation in Multiple Myeloma. Hematology American Society of Hematology Education Program, 2007, 2007, 311-316.	2.5	10
177	Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. Annals of Oncology, 2016, 27, 902-907.	1.2	10
178	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opinion on Pharmacotherapy, 2017, 18, 1975-1985.	1.8	10
179	Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.. Blood, 2006, 108, 3552-3552.	1.4	10
180	Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial.. Blood, 2009, 114, 1818-1818.	1.4	10

#	Article	IF	Citations
181	Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial. Blood, 2015, 126, 393-393.	1.4	10
182	Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8009-8009.	1.6	10
183	Vincristine degradation by serum from leukemic patients: role of myeloperoxidase. Leukemia and Lymphoma, 1996, 20, 441-446.	1.3	9
184	Kaposi's sarcoma-associated herpesvirus (KSHV) in bone marrow biopsies of patients with Waldenstrom's macroglobulinaemia. British Journal of Haematology, 1998, 102, 795-797.	2.5	9
185	DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in Multiple Myeloma. European Journal of Haematology, 2010, 84, 276-277.	2.2	9
186	Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation. Journal of Cancer, 2014, 5, 248-252.	2.5	9
187	DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. Clinical Epigenetics, 2020, 12, 163.	4.1	9
188	Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02).. Blood, 2009, 114, 529-529.	1.4	9
189	Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14). Blood, 2013, 122, 689-689.	1.4	9
190	Evolution of peripheral blood T lymphocyte subsets after allogenic or autologous hematopoietic stem cell transplantation. Immunobiology, 2014, 219, 611-618.	1.9	8
191	A Comprehensive Analysis of Cytogenetic Abnormalities in Myeloma: Results of the FISH Analysis of 1000 Patients Enrolled in the IFM99 Trials.. Blood, 2005, 106, 622-622.	1.4	8
192	Bortezomib (BOR) and High Dose Melphalan (HDM) as Conditioning Regimen Before Autologous Stem Cell Transplantation (ASCT) for De Novo Multiple Myeloma (MM): Final Results of the IFM Phase II Study VEL/MEL. Blood, 2008, 112, 160-160.	1.4	8
193	Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study. Blood, 2010, 116, 1944-1944.	1.4	8
194	Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. Blood, 2012, 120, 749-749.	1.4	8
195	Deep Igh Sequencing Identifies an Ongoing Somatic Hypermutation Process with Complex and Evolving Clonal Architecture in Myeloma. Blood, 2015, 126, 21-21.	1.4	8
196	Growth Differentation Factor 15 Is a Survival Factor for multiple myeloma cells and its plasma Concentration In Patients Is Related to Reduced Survival. Blood, 2010, 116, 614-614.	1.4	8
197	High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02. Blood, 2011, 118, 812-812.	1.4	7
198	Bortezomibâ€thalidomideâ€dexamethasone versus bortezomibâ€cyclophosphamideâ€dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. British Journal of Haematology, 2015, 168, 605-606.	2.5	6

#	Article	IF	Citations
199	Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response. Medicine (United States), 2016, 95, e5356.	1.0	6
200	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. Blood, 2009, 114, 743-743.	1.4	6
201	Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES. Blood, 2013, 122, 1933-1933.	1.4	6
202	Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial. Blood, 2016, 128, 2138-2138.	1.4	6
203	Autologous BMT for Post-Remission Therapy in Adult ALL: An Immunological Approach. Leukemia and Lymphoma, 1994, 13, 95-98.	1.3	5
204	KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS (KSHV) IN BONE MARROW BIOPSY FROM PATIENTS WITH MULTIPLE MYELOMA: PCR AMPLIFICATION OF ORF26 BUT NOT ORF72 AND ORF75 SEQUENCES. British Journal of Haematology, 2000, 108, 197-198.	2.5	5
205	Uterine chloroma, aortic thrombus and CALM/AF10 acute myeloid leukemia. Leukemia Research, 2010, 34, e88-e90.	0.8	5
206	Growth factorâ€associated graftâ€versusâ€host disease and mortality 10Âyears after allogeneic bone marrow transplantation. British Journal of Haematology, 2012, 157, 220-229.	2.5	5
207	Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2014, 49, 950-954.	2.4	5
208	Shortâ€•and longâ€term outcomes of <scp>AL</scp> amyloidosis patients admitted into intensive care units. British Journal of Haematology, 2016, 174, 868-875.	2.5	5
209	Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells. Stem Cells International, 2020, 2020, 1-9.	2.5	5
210	Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkinâ€™s Lymphoma : 36 Months Results of a Multicenter Open Label Phase II Trial (M39012 Trial).. Blood, 2004, 104, 747-747.	1.4	5
211	Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02. Blood, 2010, 116, 859-859.	1.4	5
212	Maintenance Therapy for Myeloma: How Much, How Long, and at What Cost?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 515-522.	3.8	5
213	Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT. Blood, 2012, 120, 1975-1975.	1.4	5
214	Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort. Journal of Thrombosis and Haemostasis, 2022, 20, 1859-1867.	3.8	5
215	The Future Role of Thalidomide in Multiple Myeloma. Acta Haematologica, 2005, 114, 18-22.	1.4	4
216	Predictive Factors of Survival After Thalidomide Therapy in Advanced Multiple Myeloma: Long-Term Follow-Up of a Prospective Multicenter Nonrandomized Phase II Study in 120 Patients. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 418-422.	0.4	4

#	Article	IF	Citations
217	Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study.. Blood, 2009, 114, 1876-1876.	1.4	4
218	Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status. Blood, 2008, 112, 3701-3701.	1.4	3
219	Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial. Blood, 2014, 124, 180-180.	1.4	3
220	Stem Cell Factor (SCF) for Hematopoietic Stem Cell (HSC) Mobilization: Results of the Randomized IFM 99-01 Trial.. Blood, 2004, 104, 2921-2921.	1.4	2
221	Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment.. Blood, 2009, 114, 1817-1817.	1.4	2
222	Consolidation with Bortezomib, Thalidomide and Dexamethasone After High Dose Therapy Is Feasible, Safe and Effective In De Novo Multiple Myeloma Patients Who Already Received New Drugs Containing-Induction Regimen. Blood, 2010, 116, 3041-3041.	1.4	2
223	Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study. Blood, 2012, 120, 196-196.	1.4	2
224	A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and over the Course of Treatment in Multiple Myeloma Patients. Blood, 2016, 128, 238-238.	1.4	2
225	Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial. Blood, 1999, 94, 1218-1225.	1.4	2
226	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. Blood, 2014, 124, 324-324.	1.4	2
227	Multiple Myeloma in the Era of Novel Agents. Seminars in Hematology, 2009, 46, 107-109.	3.4	1
228	Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM) Tj ETQq0 0 0 rgBT /Overlock 10	0.4	1
229	Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma. Blood, 2018, 132, 190-190.	1.4	1
230	Matched Unrelated Donor Transplantation Is Curative In Selected Patients with Diffuse Large B Cell Lymphoma: A Report of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2010, 116, 363-363.	1.4	1
231	Low Level Of NF-Kb Activity Is Associated With Higher Response Rate To Bortezomib-Based Induction Therapy In Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3106-3106.	1.4	1
232	Deep Sequencing of Immunoglobulin Loci Reveals Evolution of IgH Clone in Multiple Myeloma Patients over the Course of Treatment. Blood, 2014, 124, 2005-2005.	1.4	1
233	Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method. Blood, 2014, 124, 2036-2036.	1.4	1
234	A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications. Blood, 2016, 128, 356-356.	1.4	1

#	Article	IF	Citations
235	Molecular Prognosis in Multiple Myeloma: The IFM Experience.. Blood, 2006, 108, 3491-3491.	1.4	1
236	Long-Term Exposure to Pomalidomide-Dexamethasone in Pts with Refractory Myeloma. Blood, 2014, 124, 3466-3466.	1.4	1
237	Reply to J.C. Regelink et al. Journal of Clinical Oncology, 2010, 28, e744-e745.	1.6	0
238	Myeloma: a subclonal disease?. Hematologie, 2013, 19, 383-387.	0.0	0
239	Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. Annals of Hematology, 2018, 97, 831-837.	1.8	0
240	Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma. , 2004, , 159-182.		0
241	Autologous stem cell transplantation. , 2004, , 250-259.		0
242	A Second Course of High-Dose Cytarabine before Autologous Stem Cell Transplantation Does Not Improve Outcome of Young Acute Myeloid Leukemia Patients in First Complete Remission: Results of the BGMT 95 Study.. Blood, 2004, 104, 5194-5194.	1.4	0
243	Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLCL). A Retrospective Study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) Registry.. Blood, 2006, 108, 2946-2946.	1.4	0
244	High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients.. Blood, 2007, 110, 657-657.	1.4	0
245	Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT. Blood, 2008, 112, 458-458.	1.4	0
246	In Myeloma, the Prognostic Impact of Hyperdiploidy Is Mainly Related to the Gain of Chromosome 5. Blood, 2008, 112, 632-632.	1.4	0
247	Growth Differentiation Factor 15 Plasma Level in patients with Multiple Myeloma: A Study of Intergroupe Francophone Du Myelome. Blood, 2008, 112, 2700-2700.	1.4	0
248	Prospective Multicenter Study for Evaluating Cognitive Disorders in Hematology-Oncology: A Pilot Study of 118 Patients. Blood, 2008, 112, 1309-1309.	1.4	0
249	Long-Term Follow-up Results of IFM9903 and IFM9904 Trials Comparing Non Myeloablative Allotransplantation with Autologous Transplantation in High-Risk De Novo Multiple Myeloma.. Blood, 2008, 112, 1126-1126.	1.4	0
250	Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.. Blood, 2009, 114, 1187-1187.	1.4	0
251	Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective	1.4	0
252	Comparison of Unrelated and Sibling Donor Allogeneic Hematopoietic Cell Transplantation (HCT) for Follicular Lymphoma (FL) - From the Lymphoma Working Party, European Group for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).. Blood, 2009, 114, 874-874.	1.4	0

#	Article	IF	Citations
253	Comparison of Stromal Cells of Adipose Tissue From Multiple Myeloma Patients and Healthy Donors. Blood, 2010, 116, 2979-2979.	1.4	0
254	Gene Mutations Detected by Whole-Exome Sequencing and Recurrent Cytogenetic Abnormalities Are Independent Events in Multiple Myeloma. Blood, 2011, 118, 1816-1816.	1.4	0
255	PET Evaluation Before Autografting Has a Strong Prognostic Impact in High-Risk, Relapsed Follicular Lymphoma Patients. Blood, 2011, 118, 1612-1612.	1.4	0
256	CR As Major End-Point After Consolidation for Multiple Myeloma Patients Eligible to High Dose Therapy. Blood, 2011, 118, 1858-1858.	1.4	0
257	Efficacy of Lenalidomide in Patients with Multiple Myeloma Previously Treated by Melphalan-Prednisone and Thalidomide. Blood, 2012, 120, 4075-4075.	1.4	0
258	Prolonged Overall Survival with Pomalidomide and Dexamethasone in Myeloma Characterized with End Stage Disease.. Blood, 2012, 120, 2961-2961.	1.4	0
259	Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).. Blood, 2012, 120, 3096-3096.	1.4	0
260	Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd. Blood, 2013, 122, 3221-3221.	1.4	0
261	Prognostic Factors Affecting Progression Free Survival For Multiple Myeloma Patients Receiving Lenalidomide Maintenance After Autologous Transplantation. Follow-Up Analysis Of The IFM 2005-02 Trial. Blood, 2013, 122, 3312-3312.	1.4	0
262	Whole Exome Sequencing Of Multiple Myeloma Reveals An Heterogeneous Clonal Architecture and Genomic Evolution. Blood, 2013, 122, 399-399.	1.4	0
263	Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma.. Journal of Clinical Oncology, 2014, 32, 8592-8592.	1.6	0
264	A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus. Blood, 2014, 124, 2057-2057.	1.4	0
265	Impact on Survival Outcomes of Bone Marrow Plasma Cells Percentage and Morphology Evaluation By Conventional Microscopy in Multiple Myeloma after High Dose Therapy. Blood, 2014, 124, 3396-3396.	1.4	0
266	Outcome at first relapse after frontline RVD regimen plus lenalidomide maintenance in transplant eligible MM patients.. Journal of Clinical Oncology, 2015, 33, 8578-8578.	1.6	0
267	Genomic Landscape Predictive of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Blood, 2015, 126, 4212-4212.	1.4	0
268	Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM. Blood, 2016, 128, 3569-3569.	1.4	0
269	IFM2012-03. Blood, 2016, 128, 2128-2128.	1.4	0